Reference entry — NOT a sellable lane, NOT yet approved. Notable because it's not a GLP-1 at all — a different class (amylin) with a genuinely different mechanism. Investigational; its future rides on the CagriSema combination, filed with the FDA in Dec 2025. No dosing published here.
Cagrilintide is a long-acting amylin analog — a genuinely different mechanism from the GLP-1 drugs, acting on amylin/calcitonin receptors in the brainstem. Its future is tied to CagriSema (cagrilintide + semaglutide), the first GLP-1 + amylin combination, which produced ~20–23% weight loss in Phase 3 and was filed with the FDA in December 2025 (decision expected late 2026). The data are strong — but it is not yet approved anywhere, and it already faces a successor in Novo's own pipeline (amycretin).
- Everywhere — investigational, not approved. Cagrilintide is not available by prescription or through compounding pharmacies outside clinical trials. CagriSema is under FDA review (filed Dec 2025; decision expected late 2026). - Gray market: "research" cagrilintide is sold online but is unapproved and unregulated — unknown purity/dose. - This venture: not a sellable lane — an investigational drug
An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.
A credentialed reviewer (PharmD / PhD / MD) will be named before this entry is finalised. Until then, treat it as a working draft. Last updated July 2026 (fast-moving — re-check the late-2026 FDA decision on CagriSema).
Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.
A neutral reference and a lawful-lane shop. Registered in Spain. Information for those who seek it — never promotion.
This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia SL — Registered in Spain.